HLA-D and PLA2R1 risk alleles associate with recurrent primary membranous nephropathy in kidney transplant recipients.


Journal

Kidney international
ISSN: 1523-1755
Titre abrégé: Kidney Int
Pays: United States
ID NLM: 0323470

Informations de publication

Date de publication:
03 2021
Historique:
received: 27 04 2020
revised: 30 07 2020
accepted: 13 08 2020
pubmed: 6 9 2020
medline: 22 6 2021
entrez: 5 9 2020
Statut: ppublish

Résumé

Recurrence of primary membranous nephropathy after transplantation occurs in up to 44% of patients and is driven by PLA2R antibody. Here, we asked whether genetic determinants could improve risk prediction. First, we sequenced PLA2R1 and HLA-D loci in 248 patients with primary membranous nephropathy and identified two independent single nucleotide polymorphisms (SNPs) at risk for primary membranous nephropathy at each locus. These were rs9271188 (intergenic between HLA-DRB1 and HLA-DQA1,) and rs9275086 (intergenic between HLA-DQB1 and HLA-DQA2) at the HLA-D locus along with rs6726925 and rs13018963 at the PLA2R1 locus. Then we investigated whether primary membranous nephropathy at-risk variants were associated with recurrence in a retrospective cohort of 105 donor-recipient pairs and a replication cohort of 40 pairs. Seven SNPs located between HLA-DRB1 and HLA-DQA1 in linkage disequilibrium with rs9271188, and three SNPs in the PLA2R1 region predicted recurrence when presented by the donor, but not when presented by the recipient. The two SNPs in the HLA-D region most strongly associated with recurrence (rs9271705 and rs9271550) were confirmed in the replication cohort. A genetic risk score based on the two best predictors at each locus (rs9271705, rs9271550, rs17830558, and rs3828323) identified a group of patients with high risk of recurrence. Thus, our results suggest that the graft contributes to recurrence of primary membranous nephropathy through the disease susceptibility HLA-D and PLA2R1 SNPs in an autoimmune milieu. Further studies are needed before implementation of genetic testing for these in donor selection.

Identifiants

pubmed: 32889013
pii: S0085-2538(20)30967-4
doi: 10.1016/j.kint.2020.08.007
pii:
doi:

Substances chimiques

PLA2R1 protein, human 0
Receptors, Phospholipase A2 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

671-685

Subventions

Organisme : Medical Research Council
ID : MR/J010847/1
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn
Type : ErratumIn

Informations de copyright

Copyright © 2020. Published by Elsevier Inc.

Auteurs

Lena Berchtold (L)

Sorbonne Université, Université Pierre et Marie Curie Paris 06, Paris, France; Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche S1155, Paris, France; Division of Nephrology, Department of Internal Medicine Specialties, University Hospital of Geneva, Geneva, Switzerland.

Eric Letouzé (E)

Centre de Recherche des Cordeliers, Sorbonne Université, INSERM, France; Functional Genomics of Solid Tumor, Labex Immuno-Oncology, Equipe Labellisée Ligue Contre le Cancer, Université Paris 13, Paris, France.

Mariam Priya Alexander (MP)

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.

Guillaume Canaud (G)

Inserm U1151, Necker-Enfants Malades Hospital, Paris, France; University Paris Descartes, Sorbonne Paris Cité, Paris, France; Department of Adult Nephrology and Transplantation, Necker-Enfants Malades Hospital, Paris, France.

Anne-Els van de Logt (AV)

Department of Nephrology, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.

Patrick Hamilton (P)

Division of Cardiovascular Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.

Christiane Mousson (C)

Department of Nephrology and Transplantation, University Hospital, Dijon, France.

Vincent Vuiblet (V)

BioSpec T Laboratory, EA 7506 URCA, Reims, France; Nephropathology Department of Biopathology Laboratory, Reims University Hospital, Reims, France; Division of Nephrology, Reims University Hospital, Reims, France.

Ann M Moyer (AM)

Department of Laboratory Medicine and Pathology, Personalized Genomics Laboratory Mayo Clinic, Rochester, Minnesota, USA.

Sylvain Guibert (S)

IntegraGen, Evry, France.

Petra Mrázová (P)

Transplant Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.

Charlène Levi (C)

Department of Transplantation, Nephrology, and Clinical Immunology, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France.

Valérie Dubois (V)

Laboratoire HLA, Etablissement Français du Sang Auvergne Rhone-Alpes, Lyon, France.

Josep Maria Cruzado (JM)

Nephrology Department, Hospital Universitari Bellvitge, Bellvitge Research Institute (IDIBELL), Barcelona, Spain; RedInRen, RD16/0009/0031, University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.

Armando Torres (A)

Hospital Universitario de Canarias, Instituto de Tecnologías Biomédicas (ITB), Universidad de La Laguna, Tenerife, Spain.

Manish J Gandhi (MJ)

Division of Transfusion Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Nadhir Yousfi (N)

Sorbonne Université, Université Pierre et Marie Curie Paris 06, Paris, France; Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche S1155, Paris, France.

Vladimir Tesar (V)

Department of Nephrology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Department of Nephrology, Transplant Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.

Maryvonne Hourmant (M)

Department of Nephrology, University Hospital, Nantes, France.

Bruno Moulin (B)

Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche S 1109, Strasbourg University, Strasbourg, France; Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France; Department of Nephrology, Strasbourg University Hospital, Strasbourg, France.

Philippe Rieu (P)

Division of Nephrology, Reims University Hospital, Reims, France; Université de Reims Champagne-Ardenne, CNRS UMR 7369 (Matrice Extracellulaire et Dynamique Cellulaire, MEDyC), Reims, France.

Gabriel Choukroun (G)

Department of Nephrology, University Hospital, Amiens, France.

Christophe Legendre (C)

University Paris Descartes, Sorbonne Paris Cité, Paris, France; Department of Adult Nephrology and Transplantation, Necker-Enfants Malades Hospital, Paris, France.

Jack Wetzels (J)

Department of Nephrology, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.

Paul Brenchley (P)

Division of Cardiovascular Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.

José Aurelio Ballarín Castan (JA)

Department of Nephrology, Fundación Puigvert, Barcelona, Spain.

Hanna Debiec (H)

Sorbonne Université, Université Pierre et Marie Curie Paris 06, Paris, France; Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche S1155, Paris, France.

Pierre Ronco (P)

Sorbonne Université, Université Pierre et Marie Curie Paris 06, Paris, France; Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche S1155, Paris, France; Department of Nephrology (Day Hospital), AP-HP, Tenon Hospital, Paris, France. Electronic address: pierre.ronco@upmc.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH